We are live on ! Find out more
CVS icon

CVS Health

1,758 hedge funds and large institutions have $76.4B invested in CVS Health in 2025 Q2 according to their latest regulatory filings, with 182 funds opening new positions, 635 increasing their positions, 732 reducing their positions, and 157 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more call options, than puts

Call options by funds: $2.05B | Put options by funds: $1.7B

16% more first-time investments, than exits

New positions opened: 182 | Existing positions closed: 157

4% more capital invested

Capital invested by funds: $73.4B → $76.4B (+$2.97B)

0.8% more ownership

Funds ownership: 85.93%86.73% (+0.8%)

0% more funds holding

Funds holding: 1,7531,758 (+5)

11% less funds holding in top 10

Funds holding in top 10: 3733 (-4)

13% less repeat investments, than reductions

Existing positions increased: 635 | Existing positions reduced: 732

Holders
1,758
Holders Change
+5
Holders Change %
+0.29%
% of All Funds
23.14%
Holding in Top 10
33
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-10.81%
% of All Funds
0.43%
New
182
Increased
635
Reduced
732
Closed
157
Calls
$2.05B
Puts
$1.7B
Net Calls
+$344M
Net Calls Change
+$208M
Name Holding Trade Value Shares
Change
Change in
Stake
PGFC
301
Peapack-Gladstone Financial Corp
New Jersey
$11M -$496K -7,569 -5%
NAM
302
Nissay Asset Management
Japan
$11M +$15.8K +241 +0.2%
EMPI
303
Elo Mutual Pension Insurance
Finland
$10.7M +$308K +4,693 +3%
SCP
304
Seizert Capital Partners
Michigan
$10.6M -$28.2M -429,981 -74%
MML Investors Services
305
MML Investors Services
Massachusetts
$10.6M +$450K +6,868 +5%
AAS
306
Avantax Advisory Services
Texas
$10.5M -$523K -7,972 -5%
CCM
307
Cohen Capital Management
California
$10.5M
QOP
308
Quinn Opportunity Partners
Virginia
$10.4M -$21.6M -329,551 -69%
VPIM
309
Vanguard Personalized Indexing Management
California
$10.4M +$1.41M +21,544 +17%
TS
310
Triglav Skladi
Slovenia
$10.3M -$814K -12,415 -8%
VCM
311
Vivaldi Capital Management
Illinois
$10.1M -$143K -2,182 -1%
SSA
312
Schonfeld Strategic Advisors
New York
$10M +$92.9K +1,416 +1%
MOACM
313
Mutual of America Capital Management
New York
$10M -$104K -1,590 -1%
SPI
314
Strategic Planning Inc
Ohio
$9.88M -$146K -2,223 -2%
FVCM
315
F&V Capital Management
Florida
$9.86M -$24.9K -380 -0.3%
MMC
316
Mizuho Markets Cayman
Cayman Islands
$9.5M +$9.03M +137,750 New
OAM
317
OP Asset Management
$9.33M +$232K +3,541 +3%
Wealth Enhancement Advisory Services
318
Wealth Enhancement Advisory Services
Minnesota
$9.33M -$717K -10,929 -7%
Rafferty Asset Management
319
Rafferty Asset Management
New York
$9.22M +$1.11M +16,976 +15%
AOWM
320
Alpha Omega Wealth Management
Virginia
$9.21M -$1.01M -15,435 -10%
PL
321
Parthenon LLC
Kentucky
$9.19M -$565K -8,614 -6%
AV
322
ASR Vermogensbeheer
Netherlands
$9.16M -$33.8K -516 -0.4%
QIM
323
Quantitative Investment Management
Virginia
$9.12M +$8.67M +132,185 New
GI
324
GAMCO Investors
Connecticut
$9.09M -$211K -3,215 -2%
CIC
325
Cutler Investment Counsel
Oregon
$9.07M -$16.9K -257 -0.2%

CVS Hedge Fund Activity: Q2 2025 in Review

1,758 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2025, worth a combined $76.4B — up 4% from $73.4B a quarter earlier.

Buyers outnumbered sellers: 182 funds opened new CVS positions and 157 closed out — a net gain of 25 holders — while 635 added to existing stakes and 732 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $965M. The largest seller was Capital Research Global Investors, cutting an estimated $624M.

  • 1,758 institutional investors held CVS Health (CVS) as of Q2 2025, up from 1,753 in Q1 2025.
  • Funds reported $76.4B of CVS Health stock for Q2 2025, up 4% quarter-over-quarter.
  • 182 funds opened new CVS Health positions in Q2 2025 and 157 closed out, a net change of +25 holders.
  • The largest CVS Health buyer in Q2 2025 was Fidelity Investments, an estimated $965M added.
  • The largest CVS Health seller in Q2 2025 was Capital Research Global Investors, an estimated $624M sold.

Based on aggregated 13F filings for Q2 2025.